Abstract |
Wnt (wingless)/β- catenin signaling is critical for tumor progression and is frequently activated in colorectal cancer as a result of the mutation of adenomatous polyposis coli (APC); however, therapeutic agents targeting this pathway for clinical use are lacking. Here we report that nitazoxanide ( NTZ), a clinically approved antiparasitic drug, efficiently inhibits Wnt signaling independent of APC. Using chemoproteomic approaches, we have identified peptidyl arginine deiminase 2 (PAD2) as the functional target of NTZ in Wnt inhibition. By targeting PAD2, NTZ increased the deamination (citrullination) and turnover of β- catenin in colon cancer cells. Replacement of arginine residues disrupted the transcriptional activity, and NTZ induced degradation of β- catenin. In Wnt-activated colon cancer cells, knockout of either PAD2 or β- catenin substantially increased resistance to NTZ treatment. Our data highlight the potential of NTZ as a modulator of β- catenin citrullination for the treatment of cancer patients with Wnt pathway mutations.
|
Authors | Yi Qu, Jan Roger Olsen, Xing Yuan, Phil F Cheng, Mitchell P Levesque, Karl A Brokstad, Paul S Hoffman, Anne Margrete Oyan, Weidong Zhang, Karl-Henning Kalland, Xisong Ke |
Journal | Nature chemical biology
(Nat Chem Biol)
Vol. 14
Issue 1
Pg. 94-101
(Jan 2018)
ISSN: 1552-4469 [Electronic] United States |
PMID | 29083417
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Nitro Compounds
- Thiazoles
- beta Catenin
- PADI2 protein, human
- Protein-Arginine Deiminase Type 2
- Protein-Arginine Deiminases
- nitazoxanide
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Cell Line, Tumor
- Citrullination
- Colonic Neoplasms
(metabolism, pathology)
- Gene Knockout Techniques
- Humans
- Nitro Compounds
- Protein-Arginine Deiminase Type 2
- Protein-Arginine Deiminases
(genetics, metabolism)
- Thiazoles
(pharmacology)
- Wnt Signaling Pathway
(drug effects, genetics)
- beta Catenin
(genetics, metabolism)
|